About the company
Novo Nordisk's dominance in the global branded diabetes treatment market is a testament to its commitment to improving the lives of people living with diabetes. The company's success can be attributed to its focus on innovation, quality, and patient-centricity. As a leader in diabetes care, Novo Nordisk understands the diverse needs of individuals with diabetes. The company offers a wide range of human and modern insulins, providing options to suit different patient profiles and treatment goals. This comprehensive approach ensures that patients have access to the right treatment at the right time. In addition to insulins, Novo Nordisk has made substantial advancements in injectable diabetes treatments such as GLP-1 therapy. These treatments offer patients an alternative to insulin injections and have proven to be effective in improving glycemic control. By expanding its portfolio to include oral antidiabetic agents, Novo Nordisk has further broadened its reach in the diabetes treatment landscape, providing convenient options for patients who prefer oral medications. Recognizing the growing concern around obesity and its close relationship with diabetes, Novo Nordisk has also ventured into developing obesity treatments. These therapies aim to address the underlying causes of obesity and help individuals achieve sustainable weight management. Novo Nordisk's foray into this area reflects its commitment to holistic diabetes care and its understanding of the interplay between diabetes and other metabolic disorders. However, Novo Nordisk's contributions extend beyond diabetes care. The company's biopharmaceutical segment focuses on protein therapies for hemophilia and other disorders. By leveraging its expertise in protein engineering and production, Novo Nordisk has developed innovative treatments that have revolutionized the management of these conditions. Patients with hemophilia can now benefit from safer and more effective treatments, improving their quality of life. Novo Nordisk's dedication to research and development is pivotal in driving innovation in diabetes and biopharmaceutical treatment. The company invests significantly in clinical trials and collaborations to ensure that its products meet the highest standards of efficacy and safety. This commitment to scientific excellence has earned Novo Nordisk the trust of healthcare professionals and patients worldwide. Furthermore, Novo Nordisk has established itself as a leader in corporate responsibility. The company strives to make its treatments more accessible and affordable, particularly in low- and middle-income countries where the burden of diabetes is high. Through initiatives such as the Changing Diabetes® program, Novo Nordisk actively works to raise awareness about diabetes, improve diabetes education, and support healthcare infrastructure in underserved regions. In conclusion, Novo Nordisk's position as the leading provider of diabetes-care products stems from its unwavering dedication to improving the lives of people with diabetes. The company's diverse portfolio, encompassing insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments, ensures that patients have access to a comprehensive range of options. Novo Nordisk's foray into biopharmaceuticals, particularly in the field of protein therapies, further showcases its commitment to driving advancements in healthcare. Through its relentless pursuit of innovation, quality, and patient-centricity, Novo Nordisk continues to shape the future of diabetes care and make a positive impact on the lives of millions worldwide.
Website: https://www.novonordisk.com
Data updated: June 2, 2026
